Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/cohance-lifesciences-limited">Cohance Lifesciences</a> is undergoing a strategic transformation under new leadership, shifting focus from capability-building to commercial execution, particularly in high-growth areas like Antibody-Drug Conjugates (ADCs).</li>
 <li>The company faces significant near-term headwinds, evidenced by a 13% YoY revenue decline in FY26 due to industry-wide destocking and specific operational issues. However, an expanding late-stage (Phase III) pipeline provides medium-term visibility.</li>
 <li>Key catalysts for value creation hinge on the successful conversion of its pipeline into commercial orders, the operational normalization of its Nacharam facility, and the scaling of its specialized bioconjugation services.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Cohance Lifesciences is undergoing a strategic transformation under new leadership, shifting focus from capability-building to commercial execution, particularly in high-growth areas like Antibody-Drug Conjugates (ADCs).
  The company faces significant near-term headwinds, evidenced by a 13% YoY revenue decline in FY26 due to industry-wide destocking and specific operational issues. However, an expanding late-stage (Phase III) pipeline provides medium-term visibility.
  Key catalysts for value creation hinge on the successful conversion of its pipeline into commercial orders, the operational normalization of its Nacharam facility, and the scaling of its specialized bioconjugation services.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Cohance Lifesciences (COHANCE IN) - Aug 2026

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Anthem Biosciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a>, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for INR34B IPO. The proposed IPO will be only offer for sale, with no fresh issue.</li>
<li>Anthem Biosciences is one of three CRDMOs that possess technological capabilities in India across ADCs, RNAi, peptides, and oligonucleotides, which are among the fastest growing in the pharmaceutical industry.</li>
<li>Differentiated technological capabilities, large clientele, and exposure to commercialized molecules enhance our conviction on the sustainable growth prospect of the company. Industry backdrop is also favorable.</li>
</ul>



Anthem Biosciences (1234D IN), a Contract Research, Development, and Manufacturing Organization, has filed DRHP for INR34B IPO. The proposed IPO will be only offer for sale, with no fresh issue.
Anthem Biosciences is one of three CRDMOs that possess technological capabilities in India across ADCs, RNAi, peptides, and oligonucleotides, which are among the fastest growing in the pharmaceutical industry.
Differentiated technological capabilities, large clientele, and exposure to commercialized molecules enhance our conviction on the sustainable growth prospect of the company. Industry backdrop is also favorable.


Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

<ul>
<li>Cohance Lifesciences, a CDMO-specialty pharma platform, reported FY26 revenue of INR 2,268 crore, down 13% YoY, while Umang Vohra joined as Executive Chairman and Group CEO.</li>
<li>Umang Vohra’s appointment marks a shift from capability-building to commercial execution, just as ADC and oligonucleotide investments begin moving toward revenue contribution.</li>
<li>The recovery depends on CDMO destocking easing, Nacharam FDF normalising, and NJ Bio bioconjugation revenue scaling, delays could make H2 FY27 growth optimistic.</li>
</ul>


Cohance Lifesciences, a CDMO-specialty pharma platform, reported FY26 revenue of INR 2,268 crore, down 13% YoY, while Umang Vohra joined as Executive Chairman and Group CEO.
Umang Vohra’s appointment marks a shift from capability-building to commercial execution, just as ADC and oligonucleotide investments begin moving toward revenue contribution.
The recovery depends on CDMO destocking easing, Nacharam FDF normalising, and NJ Bio bioconjugation revenue scaling, delays could make H2 FY27 growth optimistic.


Cohance Lifesciences: Can the ADC Bet Become the Next Growth Driver?

Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Thematic (Sector/Industry)

<ul>
<li>India is the largest exporter of generic medicines, contributing 20% to global supply, and accounts for 6% of the world’s API production.</li>
<li>India’s pharma sector offers up to 75% savings in R&amp;D and 55% in manufacturing versus the US, making it essential despite tariff threats.</li>
<li>India’s CRDMO sector is expanding rapidly, with a projected market size of USD 14 billion by 2028, driven by increased demand for biologics and integrated manufacturing solutions.</li>
</ul>


India is the largest exporter of generic medicines, contributing 20% to global supply, and accounts for 6% of the world’s API production.
India’s pharma sector offers up to 75% savings in R&amp;D and 55% in manufacturing versus the US, making it essential despite tariff threats.
India’s CRDMO sector is expanding rapidly, with a projected market size of USD 14 billion by 2028, driven by increased demand for biologics and integrated manufacturing solutions.


Thematic Report: Can Tariffs Undermine India’s Pharma Advantage?

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>Our long-term bullish outlook (since early-November 2023) remains intact. With that said, we believe a 1-3-month pullback has likely begun.</li>
<li>Supports to watch are at $110 on MSCI ACWI (ACWI-US) and $41-42 on MSCI EM (EEM-US), and whether these levels hold or not will determine the severity of the pullback.</li>
<li>The S&amp;P 500 is violating its 20-day MA, Europe's EURO STOXX 50 is breaking below 4884, and Japan's TOPIX appears to be staging a false breakout at the 2800-2815 level</li>
</ul>


Our long-term bullish outlook (since early-November 2023) remains intact. With that said, we believe a 1-3-month pullback has likely begun.
Supports to watch are at $110 on MSCI ACWI (ACWI-US) and $41-42 on MSCI EM (EEM-US), and whether these levels hold or not will determine the severity of the pullback.
The S&amp;P 500 is violating its 20-day MA, Europe's EURO STOXX 50 is breaking below 4884, and Japan's TOPIX appears to be staging a false breakout at the 2800-2815 level


Pullback Underway; Getting Defensive; Long-Term RS Bottoms for Defensives Is a Reason for Caution

India

Cohance Lifesciences operates as a global Contract Development and Manufacturing Organization (CDMO) and API platform, providing services for small molecule APIs, advanced intermediates, and finished dosage forms. The company offers integrated solutions from early-stage development to commercial-scale manufacturing for pharmaceutical, biotechnology, and chemical companies. Cohance Lifesciences is headquartered in Hyderabad, India, and was founded in 2018.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cohance Lifesciences (COHANCE IN)

Primer: Cohance Lifesciences (COHANCE IN) - Aug 2026

Cohance Lifesciences is undergoing a strategic transformation under new leadership, shifting focus from capability-building to commercial...

αSK Primers

Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities

Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for an Indian IPO. The proposed IPO will be...

Tina Banerjee

Cohance Lifesciences: Can the ADC Bet Become the Next Growth Driver?

Cohance Lifesciences reports 13% YoY revenue decline at INR 2,268 crore, new CEO focuses on commercial execution as investments move towards...

Sudarshan Bhandari

Thematic Report: Can Tariffs Undermine India’s Pharma Advantage?

India leads in generic medicine exports, offering significant cost savings in R&D and manufacturing compared to the US. The country's CRDMO sector...

Nimish Maheshwari

Pullback Underway; Getting Defensive; Long-Term RS Bottoms for Defensives Is a Reason for Caution

Pullback Underway $ACWI $SPX; Getting Defensive; Long-Term RS Bottoms for Defensive Sectors is a Reason for Caution. Buys in Health Care,...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Cohance Lifesciences (COHANCE IN) - Aug 2026

Cohance Lifesciences is undergoing a strategic transformation under new leadership, shifting focus from capability-building to commercial...

αSK Primers

Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities

Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for an Indian IPO. The proposed IPO will be...

Tina Banerjee

Cohance Lifesciences: Can the ADC Bet Become the Next Growth Driver?

​Cohance Lifesciences reports 13% YoY revenue decline at INR 2,268 crore, new CEO focuses on commercial execution as investments move towards...

Sudarshan Bhandari

Thematic Report: Can Tariffs Undermine India’s Pharma Advantage?

​India leads in generic medicine exports, offering significant cost savings in R&D and manufacturing compared to the US. The country's CRDMO sector...

Nimish Maheshwari

Pullback Underway; Getting Defensive; Long-Term RS Bottoms for Defensives Is a Reason for Caution

Pullback Underway $ACWI $SPX; Getting Defensive; Long-Term RS Bottoms for Defensive Sectors is a Reason for Caution. Buys in Health Care,...

Vermilion Research

Cohance Lifesciences reports 13% YoY revenue decline at INR 2,268 crore, new CEO focuses on commercial execution as investments move towards...

India leads in generic medicine exports, offering significant cost savings in R&D and manufacturing compared to the US. The country's CRDMO sector...